Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 10.12
(0.8%)
CNY 10.12
(0.8%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 108.17 Million CNY | -67.38% |
| 2022 | 331.64 Million CNY | -31.18% |
| 2021 | 481.87 Million CNY | -48.0% |
| 2020 | 926.65 Million CNY | -38.34% |
| 2019 | 1.5 Billion CNY | -4.49% |
| 2018 | 1.57 Billion CNY | 31.25% |
| 2017 | 1.19 Billion CNY | 158.37% |
| 2016 | 464 Million CNY | 0.0% |
| 2015 | - CNY | -100.0% |
| 2014 | 100.76 Million CNY | 29.19% |
| 2013 | 78 Million CNY | 16.42% |
| 2012 | 67 Million CNY | 123.33% |
| 2011 | 30 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 67.18 Million CNY | -37.89% |
| 2024 Q3 | 30.02 Million CNY | -7.46% |
| 2024 Q2 | 59.01 Million CNY | -12.15% |
| 2023 Q3 | 174.03 Million CNY | -7.66% |
| 2023 FY | 108.17 Million CNY | -67.38% |
| 2023 Q1 | 253.1 Million CNY | -23.68% |
| 2023 Q2 | 188.47 Million CNY | -25.53% |
| 2023 Q4 | 108.17 Million CNY | -37.84% |
| 2022 Q4 | 331.64 Million CNY | -22.35% |
| 2022 FY | 331.64 Million CNY | -31.18% |
| 2022 Q2 | 427.78 Million CNY | -10.04% |
| 2022 Q1 | 475.55 Million CNY | -1.31% |
| 2022 Q3 | 427.09 Million CNY | -0.16% |
| 2021 Q3 | 564.3 Million CNY | -13.04% |
| 2021 Q2 | 648.91 Million CNY | -16.26% |
| 2021 Q1 | 774.88 Million CNY | -16.38% |
| 2021 FY | 481.87 Million CNY | -48.0% |
| 2021 Q4 | 481.87 Million CNY | -14.61% |
| 2020 FY | 926.65 Million CNY | -38.34% |
| 2020 Q4 | 926.65 Million CNY | -8.44% |
| 2020 Q3 | 1.01 Billion CNY | -17.54% |
| 2020 Q2 | 1.22 Billion CNY | -12.82% |
| 2020 Q1 | 1.4 Billion CNY | -6.32% |
| 2019 Q2 | 1.66 Billion CNY | -0.51% |
| 2019 Q1 | 1.66 Billion CNY | 6.1% |
| 2019 FY | 1.5 Billion CNY | -4.49% |
| 2019 Q4 | 1.5 Billion CNY | -4.09% |
| 2019 Q3 | 1.56 Billion CNY | -5.66% |
| 2018 Q2 | 1.55 Billion CNY | 41.14% |
| 2018 Q1 | 1.1 Billion CNY | -7.83% |
| 2018 FY | 1.57 Billion CNY | 31.25% |
| 2018 Q4 | 1.57 Billion CNY | 4.44% |
| 2018 Q3 | 1.5 Billion CNY | -3.4% |
| 2017 FY | 1.19 Billion CNY | 158.37% |
| 2017 Q1 | 585 Million CNY | 26.08% |
| 2017 Q4 | 1.19 Billion CNY | 70.05% |
| 2017 Q3 | 705 Million CNY | 20.51% |
| 2017 Q2 | 585 Million CNY | 0.0% |
| 2016 Q2 | 270 Million CNY | 22.73% |
| 2016 Q4 | 464 Million CNY | 45.0% |
| 2016 Q3 | 320 Million CNY | 18.52% |
| 2016 Q1 | 220 Million CNY | 0.0% |
| 2016 FY | 464 Million CNY | 0.0% |
| 2015 Q2 | 41.31 Million CNY | -34.43% |
| 2015 Q3 | 16.01 Million CNY | -61.22% |
| 2015 Q1 | 63 Million CNY | -37.47% |
| 2015 FY | - CNY | -100.0% |
| 2015 Q4 | - CNY | -100.0% |
| 2014 Q4 | 100.76 Million CNY | -10.66% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | 100.76 Million CNY | 29.19% |
| 2014 Q3 | 112.79 Million CNY | 0.0% |
| 2013 FY | 78 Million CNY | 16.42% |
| 2012 FY | 67 Million CNY | 123.33% |
| 2011 FY | 30 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.29 Billion CNY | 97.48% |
| Hangzhou Tigermed Consulting Co., Ltd. | 3.34 Billion CNY | 96.768% |
| Dirui Industrial Co.,Ltd. | 714.1 Million CNY | 84.852% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 90.475% |
| Maccura Biotechnology Co.Ltd | 665.16 Million CNY | 83.738% |
| Guangzhou Wondfo Biotech Co.,Ltd | 599.53 Million CNY | 81.958% |
| Guangdong Hybribio Biotech Co.,Ltd. | 56.65 Million CNY | -90.938% |
| BGI Genomics Co., Ltd. | 1.09 Billion CNY | 90.134% |
| Amoy Diagnostics Co., Ltd. | 108.34 Million CNY | 0.162% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 374.62 Million CNY | 71.125% |